## **Supplementary Materials**

Table S1. Pfizer COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 delta

variant, by age group.

Age (years)	1 dose <sup>a</sup>	dose <sup>a</sup> 2 doses 2 doses (last dose 0 to <2 months ago) <sup>b</sup> months ago) <sup>b</sup>		2 doses (last dose 4 to <6 months ago) <sup>b</sup>	3 doses (<4 months post 3 <sup>rd</sup> dose) <sup>c</sup>
12-19	53.1%	89.0%	79.5%	74.0%	96.5%
20-29	53.1%	86.5%	73.0%	48.0%	96.5%
30-39	53.1%	86.5%	73.0%	48.0%	96.5%
40-49	53.1%	86.3%	72.8%	51.8%	96.5%
50-59	53.1%	86.0%	72.5%	55.5%	95.1%
60-69	46.8%	82.8%	69.0%	50.8%	93.1%
≥70	46.8%	79.5%	65.5%	46.0%	93.1%

Sources:

Table S2. Pfizer COVID-19 vaccine effectiveness against death if infected with SARS-CoV-2 delta variant, by age group.

Age (years)	1 dose <sup>a</sup>	2 doses (last dose 0 to <2 months ago) <sup>b</sup>	2 doses (last dose 2 to <4 months ago) <sup>b</sup>	2 doses (last dose 4 to <6 months ago) <sup>b</sup>	3 doses (<2 months post 3 <sup>rd</sup> dose) <sup>b</sup>
12-59	89%	98.2%	95.3%	91.7%	98.2%
60-69	74%	97.6%	95.2%	92.0%	97.6%
≥70	74%	97.0%	95.2%	92.2%	97.0%

Sources:

Table S3. Relative probability of infection by age group and sex for SARS-CoV-2 delta variant (chance of infection in each age-sex group if overall probability of infection of 1%).

Age (years)	Male	Female
0-11	1.37%	1.30%
12-19	1.41%	1.34%
20-29	1.41%	1.29%
30-39	1.18%	1.12%
40-49	0.98%	0.94%
50-59	0.76%	0.72%
60-69	0.51%	0.49%
≥70	0.39%	0.42%
Overall	1.03%	0.97%

Sources:

Australian Government Department of Health. (2021). Coronavirus (COVID-19) case numbers and statistics – cases and deaths by age and sex. Australian Government Department of Health. Accessed 17 December 2021 from <a href="https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alerts/coronavirus-covid-19-case-numbers-and-statistics#covid19-summary-statistics">https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alerts/coronavirus-covid-19-case-numbers-and-statistics#covid19-summary-statistics</a>. [6]

Australian Government Department of Health. (2021). Coronavirus disease 2019 (COVID-19) epidemiology reports, Australia, 2020-2021. Australian Government Department of Health. Accessed 17 December 2021 from

https://www1.health.gov.au/internet/main/publishing.nsf/Content/novel coronavirus 2019 ncov weekly epidemiology reports australia 2020.htm. [7]

<sup>&</sup>lt;sup>a</sup>Chodick, G., Tene, L., Patalon, T., Gazit, S., Tov, A.B., Cohen, D., and Muhsen, K. (2021). Assessment of effectiveness of 1 dose of BNT162b2 vaccine for SARS-CoV-2 infection 13 to 24 days after immunization. *JAMA Network Open* 4(6):e2115985. <a href="https://doi.org/10.1001/jamanetworkopen.2021.15985">https://doi.org/10.1001/jamanetworkopen.2021.15985</a>.

<sup>&</sup>lt;sup>b</sup>Tartof, S.Y., Slezak, J.M., Fischer, H., Hong, V., Ackerson, B.K., Ranasinghe, O.N., et al. (2021). Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. *The Lancet* 398(10309):1407–1416. <a href="https://doi.org/10.1016/S0140-6736(21)02183-8">https://doi.org/10.1016/S0140-6736(21)02183-8</a>. [2]

Perez, J.L. (2021). Efficacy and safety of BNT162b2 booster – C4591031 2 month interim analysis. Centers for Disease Control and Prevention. Accessed 17 December 2021 from <a href="https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-11-19/02-COVID-Perez-508.pdf">https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-11-19/02-COVID-Perez-508.pdf</a>. [3]

aNasreen, S., Chung, H., He, S., Brown, K.A., Gubbay, J.B., Buchan, S.A., et al. (2021). Effectiveness of mRNA and ChAdOx1 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario. medRxiv. https://doi.org/10.1101/2021.06.28.21259420.

<sup>&</sup>lt;sup>b</sup>Andrews, N., Tessier, E., Stowe, J., Gower, C., Kirsebom, F., Simmons, R., et al. (2021). medRxiv. https://doi.org/10.1101/2021.09.15.21263583. [5]

Table S4. Probability of infection (over 2 months) based on different intensities of community transmission.

Intensity of community transmission	Cases per 100,000 over 16 weeks*	Cases per million over 2 months	Estimated % of population infected over 2 months	Equivalent to cases/day in Australia <sup>a</sup>
Zero	0	0	0.000%	0
Low*	29	157	0.016%	58
Medium*	275	1,490	0.149%	543
High*	3,544	19,197	1.920%	6998
1% chance of infection over 2 months		10,000	1.000%	3645
2% chance of infection over 2 months		20,000	2.000%	7290
5% chance of infection over 2 months		50,000	5.000%	18,225
10% chance of infection over 2 months		10,0000	10.000%	36,450

<sup>\*</sup> Definitions of low, medium, and high transmission (cases per 100,000 over 16 weeks) as defined by [9]. Low: similar to first wave in Australia. Medium: similar to second wave in VIC. High: similar to Europe in January 2021.

Source

Australian Technical Advisory Group on Immunisation. (2021). Weighing up the potential benefits and risk of harm from COVID-19 vaccine AstraZeneca. Australian Government Department of Health. Accessed 17 December 2021 from

 $\frac{https://www.health.gov.au/sites/default/files/documents/2021/06/covid-19-vaccination-weighing-up-the-potential-benefits-against-risk-of-harm-from-covid-19-vaccine-astrazeneca\_2.pdf.~ \cite{Accinetion-weighing-up-the-potential-benefits-against-risk-of-harm-from-covid-19-vaccine-astrazeneca\_2.pdf.~ \cite{Accinetion-we$ 

Table S5. Cases, deaths, and case fatality rate of COVID-19 in Australia in ages ≥12 years by age and sex, 1/1/2020 to 18/11/2021.

		Male	!	Female		
Age (years)	Cases	Deaths	Case fatality	Cases	Deaths	Case fatality
			rate			rate
12-19	11,934	1	0.01%	11,286	1	0.01%
20-29	20,066	6	0.03%	18,755	3	0.02%
30-39	17,324	12	0.07%	16,104	7	0.04%
40-49	12,277	28	0.23%	11,452	12	0.10%
50-59	9252	70	0.76%	8837	39	0.44%
60-69	5598	144	2.57%	5375	58	1.08%
≥70	5059	789	15.60%	5786	752	13.00%
Total	81,510	1,050	1.29%	77,595	872	1.12%

Sources

Australian Government Department of Health. (2021). Coronavirus (COVID-19) case numbers and statistics – cases and deaths by age and sex. *Australian Government Department of Health*. Accessed 17 December 2021 from <a href="https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alerts/coronavirus-covid-19-case-numbers-and-statistics#covid19-summary-statistics">https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alerts/coronavirus-covid-19-case-numbers-and-statistics#covid19-summary-statistics</a>. [6]

Australian Bureau of Statistics. (2021). National, state and territory population. *Australian Bureau of Statistics*. Accessed 15 December 2021 from <a href="https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/mar-2021/31010do002">https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/mar-2021/31010do002</a> 202103.xls. [8]

<sup>&</sup>lt;sup>a</sup>Based on Australian population of 21.87 million. [8]

Table S6. Estimated background incidence and fatality of myocarditis over 2 months (in populations who have not received the Pfizer COVID-19 vaccine and have not been diagnosed with COVID-19).

	over 2	f myocarditis months population) <sup>b</sup>	myocarditis (	ce of fatal over 2 months population) <sup>c</sup>	Case fatality rates from myocarditis		
Age (years) <sup>a</sup>	Male	Female	Male	Female	Male	Female	
12-19	19.0	10.0	0.3	0.3	1.3%	2.5%	
20-29	40.1	17.3	0.5	0.3	1.2%	1.7%	
30-39	40.1	20.6	0.9	0.4	2.3%	2.2%	
40-49	40.1	23.8	1.3	0.7	3.3%	3.0%	
50-59	44.4	28.7	1.1	0.9	2.6%	3.1%	
60-69	50.9	35.8	1.3	1.0	2.5%	2.9%	
≥70	53.9	39.6	1.6	1.7	3.0%	4.3%	

Sources:

Table S7. Rates of myocarditis cases per million Pfizer COVID-19 vaccine doses in Australia by age and sex.

	First dose		Secon	d dose	Third dose <sup>a</sup>	
Age (years)	Male	Female	Male	Female	Male	Female
12-19	24	6	103	25	103	25
20-29	17	7	59	19	59	19
30-39	17	8	15	6	15	6
40-49	5	5	11	9	11	9
50-59	7	2	1	4	1	4
60-69	4	6	0	0	0	0
≥70	0	4	0	0	0	0

<sup>&</sup>lt;sup>a</sup>Assumed the same rates as after second dose because no data were available for rates after third dose. Source:

Therapeutic Goods Administration. (2021). COVID-19 vaccine weekly safety report – 09-12-2021. Australian Government Department of Health. Accessed 17 December 2021 from <a href="https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report-09-12-2021">https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report-09-12-2021</a>. [12]

<sup>&</sup>lt;sup>a</sup>Australian Bureau of Statistics. (2021). National, state and territory population. *Australian Bureau of Statistics*. Accessed 15 December 2021 from <a href="https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/mar-2021/31010do002\_202103.xls">https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/mar-2021/31010do002\_202103.xls</a>. [8]

<sup>&</sup>lt;sup>b</sup>Li, X., Ostropolets, A., Makadia, R., Shoaibi, A., Rao, G., Sena, A.G., et al. (2021). Characterising the background incidence rates of adverse events of special interest COVID-19 vaccines in eight countries: multinational network cohort study. *The BMJ* 2021(373):n1435. https://doi.org/10.1101/2021.03.25.21254315. [10]

<sup>&</sup>lt;sup>c</sup>Kytö, V., Saraste, A., Voipio-Pulkki, L., and Saukko, P. (2007). Incidence of fatal myocarditis: a population-based study in Finland. American Journal of Epidemiology 165(5):570–574. https://doi.org/10.1093/aje/kwk076. [11]

Table S8. COVID-19-related myocarditis cases, deaths, and case fatality rate in ages ≥12 years by age and sex, up to 6 months post-myocarditis diagnosis.

	Male				Female					
Age	COVID-	Myocarditis	Incidence	Deaths	Case	COVID-	Myocarditis	Incidence	Deaths	Case
(years)	19 cases	cases			fatality	19 cases	cases			fatality
12-19	1106	152	13.74%	O <sup>a</sup>	<1.00%	12,291	204	1.66%	≤10 <sup>b</sup>	<1.00%
20-29	31,758	661	2.08%	$0^{a}$	<1.00%	54,404	1321	2.43%	≤10 <sup>b</sup>	<1.00%
30-39	43,723	1025	2.34%	≤10 <sup>b</sup>	<1.00%	76,988	1849	2.40%	≤10 <sup>b</sup>	<1.00%
40-49	41,971	1044	2.49%	18	1.72%	65,273	1690	2.59%	≤10 <sup>b</sup>	<1.00%
50-59	51,473	1242	2.41%	44	3.54%	68,627	1644	2.40%	23	1.40%
60-69	57,880	1286	2.22%	95	7.39%	65,223	1458	2.24%	59	4.05%
≥70	66,431	1314	1.98%	199	15.14%	74,800	1452	1.94%	183	12.60%
Total	294,342	6724	2.28%	366	5.44%	417,606	9618	2.30%	305	3.17%

<sup>&</sup>lt;sup>a</sup>For males aged 12-19 and 20-29 years, there were zero deaths out of 152 and 661 cases of myocarditis, respectively. To avoid using a 0% case fatality rate in the model, we assumed that 12-19 and 20-29 year old males had the same case fatality rate as 30-39 year old males (1.00%).

Source:

Personal communication from authors regarding patient cohort described in: Buckley, B.J.R., et al. (2021). Prevalence and clinical outcomes of myocarditis and pericarditis in 718,365 COVID-19 patients. European Journal of Clinical Investigation 51(11):e13669. https://doi.org/10.1111/eci.13679. [13]

Table S9. Age distribution of Australian population, March 2021.

Age (years)	Population	% of total population
0-11	3,828,247	14.90%
12-19	2,438,423	9.49%
20-29	3,617,689	14.08%
30-39	3,757,954	14.63%
40-49	3,296,519	12.83%
50-59	3,120,900	12.15%
60-69	2,696,731	10.50%
≥70	2,936,879	11.43%
Total	25,693,342	100.00%

Source:

<sup>&</sup>lt;sup>b</sup>Patient counts of  $\leq$ 10 were rounded up to 10 to safeguard protected healthcare data. Related case fatality rates were thus assumed to be <1.00%., with a value of 1.00% used in the model to assume the worst-case scenario.

<sup>&</sup>lt;sup>a</sup>Australian Bureau of Statistics. (2021). National, state and territory population. *Australian Bureau of Statistics*. Accessed 15 December 2021 from <a href="https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/mar-2021/31010do002\_202103.xls">https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/mar-2021/31010do002\_202103.xls</a>. [8]

Table S10. Results of manual calculations used to validate the mathematical assumptions used to parameterise the model. Values provided are from two independent modellers (blue, green) and model estimates (purple).

	Questions	Calculated estimate
1. For a 30-39 year-	a) Not vaccinated	0.022701
old male, what is the		0.022656
chance of		0.022656
symptomatic infection	b) Had one dose (administered <3 weeks ago)	0.010647
under ATAGI high		0.010626
transmission if:		0.010626
	c) Had two doses (last dose 0-<2 months ago)	0.003065
		0.003059
		0.003059
	d) Had two doses (last dose 2-<4 months ago)	0.006129
		0.006117
		0.006117
	e) Had two doses (last dose 4-<6 months ago)	0.011804
		0.011781
		0.011781
	f) Had three doses	0.000795
		0.000793
		0.000793
<b>2.</b> For a 30-39 year-	a) Not vaccinated	0.000693
old male with		0.000693
symptomatic COVID-		0.000693
19, what is the chance	b) Had one dose (administered <3 weeks ago)	0.000076
of dying from		0.000076
COVID-19 if:		0.000076
	c) Had two doses (last dose 0-<2 months ago)	0.000012
		0.000012
		0.000012
	d) Had two doses (last dose 2-<4 months ago)	0.000033
		0.000033
		0.000033
	e) Had two doses (last dose 4-<6 months ago)	0.000057
		0.000057
		0.000057
	f) Had three doses	0.000012
		0.000012
		0.000012
* 3. Under ATAGI	a) How many cases of vaccine-induced	6.700000
high transmission, for	myocarditis would we expect?	6.700000
one million 50-59		6.700000
year-old females, if	b) How many vaccine-associated myocarditis-	0.022919
5% have had no	induced deaths would we expect?	0.022919
vaccine doses, 5%	_	0.022919
have had 1 dose only,		
60% have had 2 doses		
only and 30% have		
had 3 doses:		
* <b>4.</b> For one million	a) How many symptomatic cases would we	183.0304
≥70 year-old males, if	expect over 2 months if there was ATAGI	183.2208
5% have had no	medium transmission during this time?	183.2208
vaccine doses, 5%	h) H-m many last of a COVID 10	( 270250
have had 1 dose only,	b) How many deaths from COVID-19 would we	6.379250
60% have had 2 doses	expect over 2 months if there was ATAGI	6.389558
only and 30% have	medium transmission during this time?	6.389558
had 3 doses:		
<b>5.</b> If a 60-69 year-old	a) What are her chances of developing COVID-	0.022354
female was diagnosed	19-related myocarditis?	0.022354
with COVID-19:		0.022354
		0.022334
Will Co VID 191	b) What are her chances of dying from COVID-	0.000905
	b) What are her chances of dying from COVID-19-related myocarditis (before diagnosis)?	

Additional population	c) What are her background chances of	0.000036
risk:	developing myocarditis?	0.000036
		0.000036
	d) What are her background chances of dying	0.000001
	from myocarditis?	0.000001
	•	0.000001

<sup>\*</sup>Model estimates for Questions 3 and 4 are calculated using the population level model described in section 2.1, 'Model description'.

Table S11. Comparison of symptomatic COVID-19 cases prevented by Pfizer COVID-19 vaccine versus cases of Pfizer vaccine-associated myocarditis under different intensities of community transmission. Assuming transmission of delta variant; 5% of unvaccinated, 5% received first dose, 60% received two doses; 30% received three doses; vaccine effectiveness against symptomatic infection as reported in Table S1; age-sex-specific myocarditis incidence as shown in Table S7.

Age group (years)	Community transmission intensity (probability of infection over 2 months)	Estimated C cases over 2 (per million 0% vaccinated	months	Estimated COVID-19 cases prevented over 2 months if 5% had 1st dose, 60% had 2 doses, 30% had three doses	Estimated cases of vaccine-associated myocarditis if 5% had 1st dose, 60% had 2 doses, 30% had 3 doses	Estimated cases of symptomatic COVID-19 prevented per vaccine-associated myocarditis cases
4 77	10/	0250	2270	(per million <sup>a</sup> )	(per million <sup>a</sup> )	246
All	1%	9259	2378	6881	20	246
ages ≥12 <sup>b</sup>	5%	46,295	11,889	34,406	28	1229
≥12°	10%	92,590	23,777	68,813		2458
12-19	1%	13,768	2739	11,029		121
	5%	68,840	13,696	55,144	91	606
	10%	137,679	27,391	110,288		1212
20-29	1%	13,478	3625	9853		170
	5%	67,390	18,125	49,265	58	849
	10%	134,780	36,249	98,531		1699
30-39	1%	11,536	3103	8433		351
	5%	57,679	15,513	42,167	24	1757
	10%	115,259	31,026	84,333		3514
40-49	1%	9608	2522	7086		443
	5%	48,040	12,608	35,432	16	2215
	10%	96,081	25,216	70,864		4429
50-59	1%	7352	1912	5441		777
	5%	36,762	9559	27,203	7	3886
	10%	73,523	19,118	54,405		7772
60-69	1%	5045	1475	3570		714
	5%	25,224	7373	17,851	5	3570
	10%	50,448	14,746	35,702		7140
≥70	1%	4026	1269	2757		1379
= -	5%	20,130	6347	13,783	2	6892
	10%	40,260	12,694	27,566	†	13,783

<sup>&</sup>lt;sup>a</sup>Per million population of each age group, or per million of all ages based on population distribution of Australia. [8] <sup>b</sup>Calculations for all ages based on population distribution of Australia. [8]

## References

- 1. Chodick, G., Tene, L., Patalon, T., Gazit, S., Tov, A.B., Cohen, D., and Muhsen, K. (2021). Assessment of effectiveness of 1 dose of BNT162b2 vaccine for SARS-CoV-2 infection 13 to 24 days after immunization. *JAMA Network Open* 4(6):e2115985. https://doi.org/10.1001/jamanetworkopen.2021.15985.
- 2. Tartof, S.Y., Slezak, J.M., Fischer, H., Hong, V., Ackerson, B.K., Ranasinghe, O.N., et al. (2021). Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. *The Lancet* 398(10309):1407–1416. <a href="https://doi.org/10.1016/S0140-6736(21)02183-8">https://doi.org/10.1016/S0140-6736(21)02183-8</a>.
- 3. Perez, J.L. (2021). Efficacy and safety of BNT162b2 booster C4591031 2 month interim analysis. *Centers for Disease Control and Prevention*. Accessed 17 December 2021 from <a href="https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-11-19/02-COVID-Perez-508.pdf">https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-11-19/02-COVID-Perez-508.pdf</a>.
- 4. Nasreen, S., Chung, H., He, S., Brown, K.A., Gubbay, J.B., Buchan, S.A., et al. (2021). Effectiveness of mRNA and ChAdOx1 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario. *medRxiv*. https://doi.org/10.1101/2021.06.28.21259420.
- 5. Andrews, N., Tessier, E., Stowe, J., Gower, C., Kirsebom, F., Simmons, R., et al. (2021). *medRxiv*. https://doi.org/10.1101/2021.09.15.21263583.
- 6. Australian Government Department of Health. (2021). Coronavirus (COVID-19) case numbers and statistics cases and deaths by age and sex. *Australian Government Department of Health*. Accessed 17 December 2021 from <a href="https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alert/coronavirus-covid-19-case-numbers-and-statistics#covid19-summary-statistics">https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alert/coronavirus-covid-19-case-numbers-and-statistics#covid19-summary-statistics</a>.
- 7. Australian Government Department of Health. (2021). Coronavirus disease 2019 (COVID-19) epidemiology reports, Australia, 2020-2021. *Australian Government Department of Health*. Accessed 17 December 2021 from <a href="https://www1.health.gov.au/internet/main/publishing.nsf/Content/novel\_coronavirus\_2019\_ncov\_weekly\_epidemiology\_reports\_australia\_2020.htm">https://www1.health.gov.au/internet/main/publishing.nsf/Content/novel\_coronavirus\_2019\_ncov\_weekly\_epidemiology\_reports\_australia\_2020.htm</a>.
- 8. Australian Bureau of Statistics. (2021). National, state and territory population. *Australian Bureau of Statistics*. Accessed 15 December 2021 from <a href="https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/mar-2021/31010do002">https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/mar-2021/31010do002</a> 202103.xls.
- 9. Australian Technical Advisory Group on Immunisation. (2021). Weighing up the potential benefits and risk of harm from COVID-19 vaccine AstraZeneca. *Australian Government Department of Health*. Accessed 17 December 2021 from <a href="https://www.health.gov.au/sites/default/files/documents/2021/06/covid-19-vaccination-weighing-up-the-potential-benefits-against-risk-of-harm-from-covid-19-vaccine-astrazeneca 2.pdf.</a>
- 10. Li, X., Ostropolets, A., Makadia, R., Shoaibi, A., Rao, G., Sena, A.G., et al. (2021). Characterising the background incidence rates of adverse events of special interest COVID-19 vaccines in eight countries: multinational network cohort study. *The BMJ* 2021(373):n1435. <a href="https://doi.org/10.1101/2021.03.25.21254315">https://doi.org/10.1101/2021.03.25.21254315</a>.
- 11. Kytö, V., Saraste, A., Voipio-Pulkki, L., and Saukko, P. (2007). Incidence of fatal myocarditis: a population-based study in Finland. American Journal of Epidemiology 165(5):570–574. <a href="https://doi.org/10.1093/aje/kwk076">https://doi.org/10.1093/aje/kwk076</a>.
- 12. Therapeutic Goods Administration. (2021). COVID-19 vaccine weekly safety report 09-12-2021. *Australian Government Department of Health*. Accessed 17 December 2021 from <a href="https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report-09-12-2021">https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report-09-12-2021</a>.
- 13. Buckley, B.J.R., Harrison, S.L., Fazio-Eynullayeva, E., Underhill, P., Lane, D.A., and Lip, G.Y.H. (2021). Prevalence and clinical outcomes of myocarditis and pericarditis in 718,365 COVID-19 patients. *European Journal of Clinical Investigation* 51(11):e13669. https://doi.org/10.1111/eci.13679.